Systemic treatment for lung carcinoids: from bench to bedside-Reference-Cited by-同舟云学术

Systemic treatment for lung carcinoids: from bench to bedside

Published:2019-07-04 Issue:1 Volume:8 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Torniai Mariangela¹,Scortichini Laura¹,Tronconi Francesca¹,Rubini Corrado²,Morgese Francesca¹,Rinaldi Silvia¹,Mazzanti Paola¹,Berardi Rossana¹^ORCID

Affiliation:

1. Clinica OncologicaUniversità Politecnica delle MarcheAOU Ospedali Riuniti di AnconaVia Conca 7160126AnconaItaly

2. Section of Pathological Anatomy and HistopathologyDepartment of NeuroscienceUniversità Politecnica delle MarcheAOU Ospedali Riuniti di AnconaAnconaItaly

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1186/s40169-019-0238-5

Reference182 articles.

1. Reproducibility of neuroendocrine lung tumor classification

2. Histological Typing of Lung and Pleural Tumours

3. Grading lung neuroendocrine tumors: controversies in search of a solution;Pelosi G;Histol Histopathol,2017

4. Classification of pulmonary neuroendocrine tumors: new insights;Pelosi G;Transl Lung Cancer Res,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Auranofin inhibition of thioredoxin reductase sensitizes lung neuroendocrine tumor cells (NETs) and small cell lung cancer (SCLC) cells to sorafenib as well as inhibiting SCLC xenograft growth;Cancer Biology & Therapy;2024-07-25

2. Exploring the multifaceted antitumor activity of axitinib in lung carcinoids;Frontiers in Endocrinology;2024-07-10

3. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature;Clinical Lung Cancer;2024-05

4. ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report;Lung Cancer;2024-01

5. Cabozantinib for Treating a Patient with KIF5B-RET Fusion-Positive Atypical Lung Cancer: A Case Report;2024